Repurposing recombinant IL-2 (aldesleukin) for treating human cardiovascular disease is of interest, although currently its licensed indication is limited to metastatic melanoma and metastatic renal cell carcinoma. This evidence concerns the gene IL2 and cardiovascular disorder.